Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 6 de 6
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Chem Biodivers ; : e202401104, 2024 Jun 07.
Article de Anglais | MEDLINE | ID: mdl-38847390

RÉSUMÉ

A remarkable enhancer of human glucocerebrosidase enzyme (GCase) was identified among a set of dihydroazulene-tagged iminosugars. An unprecedented 3.9-fold increase in GCase activity was detected on fibroblasts bearing the homozygous L444P mutation, which is frequently associated with neuronopathic Gaucher forms, and which commonly results refractory to chaperone-induced refolding.

2.
Chembiochem ; 25(1): e202300730, 2024 01 02.
Article de Anglais | MEDLINE | ID: mdl-37877519

RÉSUMÉ

Engineering bioactive iminosugars with pH-responsive groups is an emerging approach to develop pharmacological chaperones (PCs) able to improve lysosomal trafficking and enzymatic activity rescue of mutated enzymes. The use of inexpensive l-malic acid allowed introduction of orthoester units into the lipophilic chain of an enantiomerically pure iminosugar affording only two diastereoisomers contrary to previous related studies. The iminosugar was prepared stereoselectively from the chiral pool (d-mannose) and chosen as the lead bioactive compound, to develop novel candidates for restoring the lysosomal enzyme glucocerebrosidase (GCase) activity. The stability of orthoester-appended iminosugars was studied by 1 H NMR spectroscopy both in neutral and acidic environments, and the loss of inhibitory activity with time in acid medium was demonstrated on cell lysates. Moreover, the ability to rescue GCase activity in the lysosomes as the result of a chaperoning effect was explored. A remarkable pharmacological chaperone activity was measured in fibroblasts hosting the homozygous L444P/L444P mutation, a cell line resistant to most PCs, besides the more commonly responding N370S mutation.


Sujet(s)
Maladie de Gaucher , Glucosylceramidase , Humains , Maladie de Gaucher/traitement médicamenteux , Maladie de Gaucher/génétique , Pipéridines/pharmacologie , Pipéridines/métabolisme , Mutation , Fibroblastes , Concentration en ions d'hydrogène
3.
Org Biomol Chem ; 21(21): 4491-4503, 2023 05 31.
Article de Anglais | MEDLINE | ID: mdl-37198937

RÉSUMÉ

A collection of novel mono- and three-tailed derivatives based on a sugar (glucose) or an iminosugar (trihydroxy piperidine) featuring a terminal benzenesulfonamide were synthesized to investigate the so-called "sugar" and "azasugar" approach with the aim of exploring the activity and selectivity towards the inhibition of human carbonic anhydrases (hCAs). The synthetic approach relies on a general copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) reaction followed by an amine-isothiocyanate coupling. Biological assays were used to collect subtle information on the role of these single or multiple hydrophilic chains. Among the sugar-based inhibitors, the single-tailed compound 10 was identified as a better inhibitor than the reference compound (AAZ) towards three different hCAs, while, among the three sugar tailed derivatives, potent and selective inhibition was found for compounds 25 and 26. A promising and selective inhibitory activity was discovered for the iminosugar single-tailed compound 31 towards hCA VII (Ki = 9.7 nM).


Sujet(s)
Inhibiteurs de l'anhydrase carbonique , Carbonic anhydrases , Humains , Structure moléculaire , Relation structure-activité , Inhibiteurs de l'anhydrase carbonique/pharmacologie , Sucres , Relation dose-effet des médicaments , Carbonic anhydrases/métabolisme , Carbonic anhydrase IX/métabolisme ,
4.
Chemistry ; 29(19): e202203841, 2023 Apr 03.
Article de Anglais | MEDLINE | ID: mdl-36598148

RÉSUMÉ

Piperidine-based photoswitchable derivatives have been developed as putative pharmacological chaperones for glucocerebrosidase (GCase), the defective enzyme in Gaucher disease (GD). The structure-activity study revealed that both the iminosugar and the light-sensitive azobenzene are essential features to exert inhibitory activity towards human GCase and a system with the correct inhibition trend (IC50 of the light-activated form lower than IC50 of the dark form) was identified. Kinetic analyses showed that all compounds are non-competitive inhibitors (mixed or pure) of GCase and the enzyme allosteric site involved in the interaction was identified by means of MD simulations. A moderate activity enhancement of mutant GCase assessed in GD patients' fibroblasts (ex vivo experiments) carrying the most common mutation was recorded. This promising observation paves the way for further studies to improve the benefit of the light-to-dark thermal conversion for chaperoning activity.


Sujet(s)
Maladie de Gaucher , Glucosylceramidase , Humains , Glucosylceramidase/génétique , Glucosylceramidase/métabolisme , Maladie de Gaucher/traitement médicamenteux , Maladie de Gaucher/génétique , Pliage des protéines , Fibroblastes/métabolisme , Mutation , Antienzymes/pharmacologie
5.
Org Biomol Chem ; 20(8): 1637-1641, 2022 02 23.
Article de Anglais | MEDLINE | ID: mdl-35107482

RÉSUMÉ

Light-switchable inhibitors of the enzyme ß-glucocerebrosidase (GCase) have been developed by anchoring a specific azasugar to a dihydroazulene or an azobenzene responsive moiety. Their inhibitory effect towards human GCase, before and after irradiation are reported, and the effect on thermal denaturation of recombinant GCase and cytotoxicity were studied on selected candidates.


Sujet(s)
Composés azoïques/pharmacologie , Azulènes/pharmacologie , Antienzymes/pharmacologie , Glucosylceramidase/antagonistes et inhibiteurs , Composés azoïques/synthèse chimique , Composés azoïques/composition chimique , Azulènes/synthèse chimique , Azulènes/composition chimique , Lignée cellulaire , Survie cellulaire/effets des médicaments et des substances chimiques , Antienzymes/synthèse chimique , Antienzymes/composition chimique , Glucosylceramidase/métabolisme , Humains , Lumière , Structure moléculaire , Processus photochimiques
6.
Molecules ; 25(19)2020 Oct 02.
Article de Anglais | MEDLINE | ID: mdl-33023214

RÉSUMÉ

Pharmacological chaperones (PCs) are small compounds able to rescue the activity of mutated lysosomal enzymes when used at subinhibitory concentrations. Nitrogen-containing glycomimetics such as aza- or iminosugars are known to behave as PCs for lysosomal storage disorders (LSDs). As part of our research into lysosomal sphingolipidoses inhibitors and looking in particular for new ß-galactosidase inhibitors, we report the synthesis of a series of alkylated azasugars with a relative "all-cis" configuration at the hydroxy/amine-substituted stereocenters. The novel compounds were synthesized from a common carbohydrate-derived piperidinone intermediate 8, through reductive amination or alkylation of the derived alcohol. In addition, the reaction of ketone 8 with several lithium acetylides allowed the stereoselective synthesis of new azasugars alkylated at C-3. The activity of the new compounds towards lysosomal ß-galactosidase was negligible, showing that the presence of an alkyl chain in this position is detrimental to inhibitory activity. Interestingly, 9, 10, and 12 behave as good inhibitors of lysosomal ß-glucosidase (GCase) (IC50 = 12, 6.4, and 60 µM, respectively). When tested on cell lines bearing the Gaucher mutation, they did not impart any enzyme rescue. However, altogether, the data included in this work give interesting hints for the design of novel inhibitors.


Sujet(s)
Glucides/composition chimique , Conception de médicament , Antienzymes/pharmacologie , Cétones/composition chimique , Pipéridines/synthèse chimique , Pipéridines/pharmacologie , beta-Galactosidase/antagonistes et inhibiteurs , bêta-Glucosidase/antagonistes et inhibiteurs , Antienzymes/synthèse chimique , Antienzymes/composition chimique , Humains , Leucocytes/effets des médicaments et des substances chimiques , Leucocytes/métabolisme , Pipéridines/composition chimique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...